Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Small Fiber Neuropathy in People with MS with Neuropathic Pain and Dysautonomia: A Case Series
Multiple Sclerosis
P9 - Poster Session 9 (5:30 PM-6:30 PM)
12-005
The prevalence of neuropathic pain in Multiple Sclerosis (MS) has been reported to be 20-86% and often presents as extremity pain. Furthermore, patients with MS have been found to have evidence of sudomotor dysfunction and elevated vibration perception. Collectively these findings have been associated with increased neurological disability. These symptoms are suggestive of a peripheral neuropathy, specifically a small fiber neuropathy involving A-delta and C fiber dysfunction. However, it is often thought that these symptoms are the result of a central process and thus little investigation is put into the potential for a peripheral cause. 

NA

 

 

 


Five patients with diagnosis of MS meeting McDonald criteria whom were experiencing neuropathic pain and dysautonomia not explained by the location of their CNS lesions on MRI were evaluated for small fiber neuropathy. Patients completed MGH small fiber symptom survey along with COMPASS-31 and underwent skin punch biopsy at two sites, one distal and one proximal on their lower extremity. Biopsies were sent to a CLIA certified laboratory and stained with PGP9.5, and intraepidermal nerve fiber density was measured. 
All patients were found to have reduced IENFD, four of which had significantly decreased IENFD meeting criteria for a diagnosis of small fiber neuropathy and one had borderline low IENFD with history suggestive of mild small fiber neuropathy. Four of these patients were being treated with immunotherapy for their MS at the time of biopsy. 
Damage to peripheral A-delta and C fibers may account for symptoms of neuropathic pain and autonomic abnormalities in patients diagnosed with MS. The small fiber neuropathy found in some patients with MS may not be responsive to immunotherapy for MS and may exist and contribute to overall disability in patients despite having stable MRI findings. This is an important point to consider when evaluating and treating people with MS.
Authors/Disclosures
Mary Kelley, DO
PRESENTER
Dr. Kelley has nothing to disclose.
Leorah Aude Emmanuelle Freeman, MD, PhD (Dell Medical School, The University of Texas at Austin) Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffman La-Roche. Dr. Freeman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech, Inc. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi-Genzyme. Dr. Freeman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Texas Neurological Society. Dr. Freeman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for WebMD. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for MSAA. The institution of Dr. Freeman has received research support from Genentech. The institution of Dr. Freeman has received research support from NIH/NINDS. The institution of Dr. Freeman has received research support from NIH/NINDS. The institution of Dr. Freeman has received research support from PCORI. The institution of Dr. Freeman has received research support from EMD Serono. Dr. Freeman has received personal compensation in the range of $500-$4,999 for serving as a Participant in educational interview with Multiple Sclerosis Association of America.
Ethan Isaac Meltzer, MD (Dell Medical School, The University of Texas at Austin) Dr. Meltzer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon therapeutics. Dr. Meltzer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Meltzer has received research support from Genentech. Dr. Meltzer has received publishing royalties from a publication relating to health care.
Ashlea Lucas, PA Ms. Lucas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Ms. Lucas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyers Squibb.
Helen Onuorah, Other (Dell Medical School - The University of Texas at Austin) Ms. Onuorah has nothing to disclose.